Are you living with Waldenstrom Macroglobulinemia (WM)?
Our clinical research study is enrolling now!
Consider joining the CLOVER-WaM pivotal study, a clinical research study for people with WM.
Participants in the CLOVER-WaM study will be given a new study therapy, called CLR 131, to see if it may help manage their WM. The study therapy is an intravenous infusion given up to 4 times over 3 months through an IV and each infusion takes about 20 minutes. This study therapy is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency.
The study therapy is a targeted cytotoxic radiotherapeutic product, meaning it is designed to specifically kill cancer cells. Previous clinical research studies of the study therapy have demonstrated good response rates. The goal of the CLOVER-WaM study is to confirm the results from those studies so that more people may benefit from the study therapy. You can find out more about those studies and the study therapy on the Cellectar Biosciences website.
Note: The study therapy, CLR 131, is an investigational study therapy. An investigational study therapy is one that has not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency.